May 14, 2021
Authored and Edited by Sneha Nyshadham; Caitlin E. O'Connell; Elizabeth D. Ferrill
In Pac. Biosciences of California, Inc. v. Oxford Nanopore Techs., Inc., No. 20-2155 (Fed. Cir. May 11, 2021), the Federal Circuit affirmed the district court’s decision denying Pacific Biosciences’ motion for judgment as a matter of law and for a new trial on enablement.
Pacific Biosciences sued Oxford for patent infringement of its patents directed to methods for sequencing a nucleic acid using nanopore technology. The jury found that all of the asserted claims were infringed, but also found they were invalid for lack of enablement. Pacific Biosciences moved for judgment as a matter of law and a new trial on enablement. The district court denied the motion finding that the record as a whole, including the statements of Oxford’s expert, supported the jury’s verdict.
On appeal, the Federal Circuit found substantial evidence supporting non-enablement. In reaching this conclusion, the Court noted that the first successful nanopore sequencing of biological DNA molecules did not occur until 2011 and that Pacific Biosciences had no evidence of actual reduction to practice to undermine Oxford’s evidence of non-enablement. Thus, the Court concluded that the record supported the jury’s conclusion that the disclosure of the asserted patents did not enable the full scope of the asserted claims.
infringement, Reduction to Practice, Enablement (35 USC § 112), validity, United States Court of Appeals for the Federal Circuit (CAFC)
Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Conference
Boston Intellectual Property Law Association 4th Annual Symposium
April 10-11, 2024
Boston
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.